'Require money 3 years from now? Shift to largecaps from mid & smallcaps'

A large part of the rally in the equity benchmark was led by a handful of large-cap stocks. Now, most of those have fallen substantially and are available much cheaper.

April 28, 2020 / 01:06 PM IST

Someone who has a requirement for funds three years from now should probably look at shifting from midcaps and small caps to large caps because it will likely take longer for them to recover, Jashan Arora, Director at Master Capital Services, said in an interview with Moneycontrol’s Kshitij Anand.

Edited excerpt:

Q) A better week for Indian markets, but it looks like 9,300 is a crucial resistance level for the Nifty50. What are your views on the market?

A) The Nifty50 has formed another bearish candle pattern on the weekly time frame charts. As the broader trend is down, the Nifty may face hurdles at higher levels.

Close

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show
Q) Small & midcaps underperformed. What should investors do if they have small & midcap focused portfolios? Stay or redeem?

A) As you know, the COVID-19 pandemic has created a unique situation in the market. Nobody is sure how the situation is going to unravel, and you should be extremely cautious about your finances and investments.

Specifically, on whether mid-and small-cap investments should be sold, the answer is no. If you think growth will come back, is really in midcap and small-cap companies where the performance can be spectacular over a three to five-year timeframe.

But, when the equity market bounces back after normalcy is restored, the large caps would recover the fastest. With that in mind, someone who has a requirement for funds three years from now should probably look at shifting from mid-caps and small caps to large caps because it will likely take longer for them to recover.

A large part of the rally in the equity benchmark was led by a handful of large-cap stocks. Now, most of those have fallen substantially and are available much cheaper.

Q) Franklin Templeton shuts down six credit risk strategy debt funds. This is the second casualty of COVID-19 after IndiaNivesh. Do you think that investors will again lose faith just like what we saw post-2008 financial crisis?

A) Given the heightened risk aversion of banks, higher withdrawals from funds began, which led to funds selling bonds at a lower price.

There is a poor appetite for various debt securities and very thin volumes, and the problem has evidently accentuated for low rated corporate bonds.

In a positive scenario, if the COVID-19 issue is resolved and the bond market goes back to normal, then there’s a possibility that the fund house will be able to sell some of the debt even before maturity.


But, when that will happen and whether that will happen is uncertain at this point. We have to hope that the companies, whose debt they have invested in, continue to remain in a position to honour their obligations.The Franklin management did point out there could be staggered payments made to investors from the wound up fund, in the form of coupon payments and maturity proceeds. It’s a small cheer, but that’s what there is at present.

Q) Looking at so much of volatility – are there any all-weather stocks which one can look at?

A) Businesses like FMCG (food and sanitation), pharmaceuticals, telecom that people are buying as usual, would probably not be impacted much, so the stocks of these sectors could be the best bet to invest in such a time of volatility.

Disclaimer: The views and investment tips expressed by investment experts on Moneycontrol.com are their own and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

Kshitij Anand is the Editor Markets at Moneycontrol.

stay updated

Get Daily News on your Browser
Sections